Blog

News & Views

Sort by

Bionest

ASH 2021 Update: Part 2

A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.

Bionest

ASH 2021 Update: Part One

Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021

Bionest

What’s Next for mRNA?

Beyond COVID and cancer: In which indications will we see mRNA technology succeed next? And what technological advances might next-generation mRNA platforms offer over those used in the COVID-19 vaccines?
Load More